We partner with life sciences and health systems to deliver integrated dermatology evidence from clinical development to care delivery, supporting decisions at every stage.
We partner with life sciences and health systems to deliver integrated dermatology evidence from clinical development to care delivery, supporting decisions at every stage.
World-class dermatology expertise
Our work has shown us what the field actually needs: not just another retrospective data source or another standalone clinical trial, but a hybrid system that keeps generating evidence on the same patients as the questions evolve. Our approach guides the decisions that matter most to clinical programs in active development as they arise:
At enrollment, we capture structured and unstructured EHR data and patients consent to prospective data collection. The starting point is richer than claims or registry data alone, and the same patient stays in the system from there.
The same patients, followed over years. Continuously updated structured and unstructured EHR data alongside the prospectively collected measures from enrollment. The substrate for natural history, disease characterization, treatment patterns, and comparative effectiveness.
Programs that need additional PROs, biomarkers, imaging, or other measures can activate them through dedicated protocols layered on the same patient population.
A network of activated sites and a continuously enrolled patient population already in the system, ready to support embedded prospective studies, external control arms, and trial work that draws on what's already running.
Patients enrolled before approval and followed past launch on the same continuous infrastructure, with partner-specific protocols providing the rigorous structure required for post-authorization safety, real-world effectiveness, and long-term outcomes work.
Clinical development
Translational and Study teams
Program teams
Disease characterization, natural history, and feasibility informed by longitudinal cohort data across diverse populations.
Protocol design and population selection grounded in real clinical contexts, including the patient subgroups underrepresented or systematically excluded from trials.
Prospective studies and clinical trials run within Pedestal's cohort and site infrastructure.
External control arms.
Sub-phenotyping and risk stratification.
Regulatory
HEOR / Market Access
Payers
Medical Affairs
Post-authorization safety studies.
Supplementation of regulatory submissions with longitudinal evidence.
External control arm contributions to FDA and EMA filings.
Comparative effectiveness.
Market access evidence on how patients receiving advanced therapy in routine practice compare to trial populations.
Publication strategy and support.
Clinicians
Health systems
Care delivery teams
PI-led research
Treatment pattern characterization in routine practice.
Long-term effectiveness and safety.
Clinical decision support evidence.
Therapeutic inertia and treat-to-target gap analyses.
Partnership infrastructure for clinician-led research and publications.
Pedestal Health's longitudinal AD cohort, designed in 2020 across US, Canadian, and European sites, with multi-year follow-up, PROs, and biospecimens — has supported clinical research as advanced systemic therapy in AD expanded.
The cohorts referenced here are managed under longstanding research protocols established by Pedestal Health (formerly Target RWE) and our academic partners. Protocol names including TARGET-DERM and TARGET-NASH appear in published literature and are referenced where relevant for scientific accuracy.
Cohort launch
Cohort design and rationale published. International multi-site enrollment of pediatric and adult AD patients across academic and community settings. Designed to generate the kind of long-term comparative effectiveness, safety, and natural history data that registration trials cannot capture.
Disparities, severity, and PRO alignment
Healthcare disparities characterized across racial and ethnic subgroups, with disease severity, PROs, and advanced systemic therapy utilization rates compared. Difficult-to-treat AD sites (head, neck, face, hand) and their incremental quality-of-life burden quantified. Correlation of vIGA-AD with POEM and DLQI established to assess how clinician- and patient-reported severity track in real-world practice.
Therapeutic inertia and treat-to-target outcomes
Twelve-month longitudinal analysis of patients with moderate-to-severe AD on systemic therapy who failed to achieve AHEAD treat-to-target goals — quantifying both the prevalence of therapeutic inertia and its impact on patient-reported outcomes over time. Independent and combined effects of optimal itch (WI-NRS) and skin clearance (vIGA-AD) on POEM, DLQI, sleep, and pain established.
Active multi-partner work across decision categories
Machine-learning-based identification of moderate-to-severe AD in EHR data with Amgen. Disparities in advanced therapy access across racial and ethnic groups with AbbVie. Persistent inadequate disease control and therapeutic inertia characterized longitudinally. Real-world characteristics of patients initiating advanced systemic therapy described.
International scope. Multiple active partners. Three kinds of decisions, supported continuously across six years and the entire transformation of the AD systemic therapy landscape.
Wherever your program is, there's a way in: a full evidence plan, a single study, or a conversation about what's possible.
By submitting this form, you consent to your information used by Pedestal Health for the purpose of contacting you to better understand your potential interest in Pedestal Health and/or its services. For more information, see our privacy policy.